Literature DB >> 24093174

Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma.

Jolieke G van Oosterwijk1, Jakob K Anninga, Hans Gelderblom, Anne-Marie Cleton-Jansen, Judith V M G Bovée.   

Abstract

Osteosarcoma and chondrosarcoma are the 2 most common malignant bone tumors. This review discusses the clinicopathologic features, recent preclinical developments, and targets currently being or to be validated in the clinic.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone tumor; Chemotherapy; Chondrosarcoma; Hypoxia; Osteosarcoma; Sarcoma; Targeted therapy

Mesh：

Year:  2013        PMID： 24093174     DOI： 10.1016/j.hoc.2013.07.012

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  25 in total

Review 1.  Progress in the chemotherapeutic treatment of osteosarcoma.

Authors:  Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

2.  The Investigation of ADAMTS16 in Insulin-Induced Human Chondrosarcoma Cells.

Authors:  Ozlem Cakmak; Ismail Comertoglu; Ridvan Firat; Haci Kemal Erdemli; S Fatih Kursunlu; Sumeyya Akyol; Veli Ugurcu; Aynur Altuntas; Bahattin Adam; Kadir Demircan
Journal:  Cancer Biother Radiopharm       Date:  2015-08       Impact factor: 3.099

Review 3.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

4.  Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma.

Authors:  Ning Lu; Tao Lin; Lin Wang; Mei Qi; Zhiyan Liu; Hongyan Dong; Xiying Zhang; Chunyan Zhai; Yan Wang; Long Liu; Lei Xiang; Lei Qi; Bo Han; Jinsong Li
Journal:  Tumour Biol       Date:  2015-01-09

5.  MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

6.  Tissue factor associates with survival and regulates tumour progression in osteosarcoma.

Authors:  Chris Tieken; Michiel C Verboom; Wolfram Ruf; Hans Gelderblom; Judith V M G Bovée; Pieter H Reitsma; Anne-Marie Cleton-Jansen; Henri H Versteeg
Journal:  Thromb Haemost       Date:  2016-01-14       Impact factor: 5.249

7.  Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.

Authors:  Audrey Lamora; Mathilde Mullard; Jérôme Amiaud; Régis Brion; Dominique Heymann; Françoise Redini; Franck Verrecchia
Journal:  Oncotarget       Date:  2015-06-10

8.  Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013.

Authors:  Annemiek M van Maldegem; Judith Vmg Bovée; Hans Gelderblom
Journal:  Clin Sarcoma Res       Date:  2014-08-12

9.  Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis.

Authors:  Daniela Egas-Bejar; Pete M Anderson; Rishi Agarwal; Fernando Corrales-Medina; Eswaran Devarajan; Winston W Huh; Robert E Brown; Vivek Subbiah
Journal:  Oncoscience       Date:  2014-03-12

10.  No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Authors:  Elisabeth F P Peterse; Arjen H G Cleven; Yvonne De Jong; Inge Briaire-de Bruijn; Jonathan A Fletcher; Erik H J Danen; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.